sunitinib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702632
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
sunitinib-resistant FLT3 mutants
Click the image above or here to open this pathway in the Pathway Browser

Sunitinib is a first generation type II tyrosine kinase inhibitor with broad specifity for receptor tyrosine kinases, including FLT3. This pathway describes FLT3 mutants that show resistance to sunitinib-mediated inhibition (reviewed in Kazi and Roonstrand, 2019).

Literature References
PubMed ID Title Journal Year
31066629 FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Kazi, JU, Rönnstrand, L

Physiol. Rev. 2019
Participants
Events
Participant Of
hasEvent
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!